LNTH Lantheus (LNTH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0001521036
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
254
13F, latest reported quarter
What the filings say about LNTH
Congress, 1 year
No trades
Last one: purchase, 2025-01-28
Lantheus insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Lantheus Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 19, 2025.
- The trade is 96.8% of the 3,477,227 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider WEHRLY MARK C sold about $188.9M of LNTH on Aug 20, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 19, 2025.
- The trade is 96.8% of the 3,477,227 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Dapice Joshua J. sold about $188.9M of LNTH on Aug 20, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.6% of the 6,842,227 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider WEHRLY MARK C sold about $2.3M of LNTH on Aug 19, 2025, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.6% of the 6,842,227 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Dapice Joshua J. sold about $2.3M of LNTH on Aug 19, 2025, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Jun 5, 2025.
- The trade is 2.8% of the 108,214 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Blanchfield Paul sold about $163.9K of LNTH on Aug 13, 2025; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.196 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
254 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
+0.5% year over year
below 52% of Pharma & Biotech
Margin
15.2% net margin
more than 85% of Pharma & Biotech
Buybacks
$300.0M repurchased, FY to 2025-12-31
more than 81% of Pharma & Biotech
Short interest
6.2% of the float short (float per yahoo 2026-10-27) · 4.5 days to cover · settled 2026-10-15
more than 55% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LNTH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+76.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LNTH: institutional holders (13F)
13F holdings, latest reported quarter
8,397,642 sh
$931.6M
5,583,479 sh
$619.4M
5,188,416 sh
$575.6M
3,879,971 sh
$430.4M
3,238,471 sh
$359.3M
Congress trades in LNTH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-01-28 · disclosed 14 days later
$1,001 - $15,000
Bought 2025-01-13 · disclosed 29 days later
$1,001 - $15,000
Bought 2025-01-08 · disclosed 34 days later
$1,001 - $15,000
Bought 2025-01-07 · disclosed 35 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LNTH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LNTH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
LIVE OAK HEALTH SCIENCES FUND
$2.6M position · as of 2026-07-31
4.7%
Saratoga Health & Biotechnology Fund
$486.6K position · as of 2026-05-31
4.6%
RIVER OAK DISCOVERY FUND
$788.1K position · as of 2026-07-31
4.1%
Private Capital Management Value Fund
$2.7M position · as of 2026-07-31
3.8%
Reinhart Genesis PMV Fund
$26.0M position · as of 2026-05-31
3.6%
The Acquirers Fund
$1.0M position · as of 2026-07-31
3.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01 · 2022-03-30
$4.5M
Department Of Veterans Affairs
DELIVERY ORDER FOR PYLARIFY · 2025-11-04
$3.8M
Department Of Veterans Affairs
PYLARIFY INJECTIONS · 2022-12-15
$3.7M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Lantheus Holdings Inc Political Action Committee (Lantheus Pac)
Cycle 2026 · $61K spent
$91.5K
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 254 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LNTH financials
Revenue growth
+0.5%
XBRL, annual
Net margin
15.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LNTH
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.5B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $935.1M |
| FY Dec 2021 | $425.2M |
| Jun 2026 | $388.2M |
| Mar 2026 | $377.3M |
| Dec 2025 | $406.8M |
| Sep 2025 | $384.0M |
| Jun 2025 | $378.0M |
| Mar 2025 | $372.8M |
| Dec 2024 | $391.1M |
| Sep 2024 | $378.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+17.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LNTH
| FY Dec 2025 | +15.2% |
| FY Dec 2024 | +20.4% |
| FY Dec 2023 | +25.2% |
| FY Dec 2022 | +3.0% |
| FY Dec 2021 | -16.8% |
| Jun 2026 | +19.3% |
| Mar 2026 | +31.4% |
| Dec 2025 | +13.3% |
| Sep 2025 | +7.2% |
| Jun 2025 | +20.8% |
| Mar 2025 | +19.6% |
| Dec 2024 | -3.0% |
| Sep 2024 | +34.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$387.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LNTH
| FY Dec 2025 | $354.1M |
| FY Dec 2024 | $493.1M |
| FY Dec 2023 | $259.9M |
| FY Dec 2022 | $21.8M |
| FY Dec 2021 | $53.9M |
| Jun 2026 | $89.9M |
| Mar 2026 | $121.9M |
| Dec 2025 | $81.4M |
| Sep 2025 | $94.7M |
| Jun 2025 | $79.1M |
| Mar 2025 | $98.8M |
| Dec 2024 | $141.4M |
| Sep 2024 | $159.3M |
At each fiscal year end
Single quarter
Debt to equity
0.44x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity LNTH
| FY Dec 2025 | 0.52x |
| FY Dec 2024 | 0.52x |
| FY Dec 2023 | 0.69x |
| FY Dec 2022 | 1.25x |
| FY Dec 2021 | 0.38x |
| Jun 2026 | 0.44x |
| Mar 2026 | 0.47x |
| Dec 2025 | 0.52x |
| Sep 2025 | 0.51x |
| Jun 2025 | 0.49x |
| Mar 2025 | 0.49x |
| Dec 2024 | 0.52x |
| Sep 2024 | 0.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.72x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt LNTH
| FY Dec 2025 | 0.69x |
| FY Dec 2024 | 0.96x |
| FY Dec 2023 | 0.54x |
| FY Dec 2022 | 0.50x |
| FY Dec 2021 | 0.31x |
| Jun 2026 | 0.72x |
| Mar 2026 | 0.71x |
| Dec 2025 | 0.69x |
| Sep 2025 | 0.80x |
| Jun 2025 | 0.93x |
| Mar 2025 | 0.93x |
| Dec 2024 | 0.96x |
| Sep 2024 | 0.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+22.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LNTH
| FY Dec 2025 | +21.4% |
| FY Dec 2024 | +32.8% |
| FY Dec 2023 | +51.7% |
| FY Dec 2022 | +6.2% |
| FY Dec 2021 | -14.6% |
| Jun 2026 | +22.2% |
| Mar 2026 | +23.5% |
| Dec 2025 | +21.4% |
| Sep 2025 | +14.6% |
| Jun 2025 | +24.7% |
| Mar 2025 | +24.1% |
| Dec 2024 | +32.8% |
| Sep 2024 | +45.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LNTH
| FY Dec 2025 | +11.1% |
| FY Dec 2024 | +17.2% |
| FY Dec 2023 | +22.0% |
| FY Dec 2022 | +2.6% |
| FY Dec 2021 | -8.2% |
| Jun 2026 | +12.2% |
| Mar 2026 | +12.7% |
| Dec 2025 | +11.1% |
| Sep 2025 | +7.8% |
| Jun 2025 | +13.4% |
| Mar 2025 | +13.1% |
| Dec 2024 | +17.2% |
| Sep 2024 | +23.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+19.7%
operating income after a 24.2% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital LNTH
| FY Dec 2025 | +22.6% |
| FY Dec 2024 | +47.0% |
| FY Dec 2023 | +46.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +19.7% |
| Mar 2026 | +20.8% |
| Dec 2025 | +22.6% |
| Sep 2025 | +22.0% |
| Jun 2025 | +33.6% |
| Mar 2025 | +40.7% |
| Dec 2024 | +47.0% |
| Sep 2024 | +47.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+15.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LNTH
| FY Dec 2025 | +17.1% |
| FY Dec 2024 | +28.5% |
| FY Dec 2023 | +28.7% |
| FY Dec 2022 | +3.9% |
| FY Dec 2021 | -7.8% |
| Jun 2026 | +15.4% |
| Mar 2026 | +15.2% |
| Dec 2025 | +17.1% |
| Sep 2025 | +21.8% |
| Jun 2025 | +24.9% |
| Mar 2025 | +26.6% |
| Dec 2024 | +28.5% |
| Sep 2024 | +36.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
24.19x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing LNTH
| FY Dec 2025 | 19.81x |
| FY Dec 2024 | 20.57x |
| FY Dec 2023 | 13.36x |
| FY Dec 2022 | 127.40x |
| FY Dec 2021 | n/a |
| Jun 2026 | 26.86x |
| Mar 2026 | 18.32x |
| Dec 2025 | 19.81x |
| Sep 2025 | 21.73x |
| Jun 2025 | 21.89x |
| Mar 2025 | 27.89x |
| Dec 2024 | 20.57x |
| Sep 2024 | 18.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.5B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value LNTH
| FY Dec 2025 | $4.6B |
| FY Dec 2024 | $5.9B |
| FY Dec 2023 | $4.1B |
| FY Dec 2022 | $3.7B |
| FY Dec 2021 | $2.0B |
| Jun 2026 | $7.2B |
| Mar 2026 | $5.0B |
| Dec 2025 | $4.6B |
| Sep 2025 | $3.7B |
| Jun 2025 | $5.5B |
| Mar 2025 | $6.3B |
| Dec 2024 | $5.9B |
| Sep 2024 | $7.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield LNTH
| FY Dec 2025 | +8.0% |
| FY Dec 2024 | +7.9% |
| FY Dec 2023 | +6.1% |
| FY Dec 2022 | +0.6% |
| FY Dec 2021 | +2.8% |
| Jun 2026 | +5.4% |
| Mar 2026 | +7.7% |
| Dec 2025 | +8.0% |
| Sep 2025 | +11.9% |
| Jun 2025 | +8.5% |
| Mar 2025 | +7.1% |
| Dec 2024 | +7.9% |
| Sep 2024 | +6.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
2.32x
P/E over trailing EPS growth of 10%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing LNTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 2.58x |
| Mar 2026 | 1.00x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $935.1M |
| Gross profit | $942.0M | $988.3M | $709.5M | $581.7M |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M |
| EPS (diluted) | 3.41 | 4.36 | 4.65 | 0.40 |
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M |
| Cash | $359.1M | $912.8M | $713.7M | $415.7M |
| Long-term debt | $568.7M | $565.3M | $561.7M | $557.7M |
| Buybacks | $300.0M | $100.0M | $0 | $75.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
LNTH Stock Sonar score 5/7 axes
Find similar shapesCompareLNTH ranks highest on profitability (83rd percentile) and institutional and government (83rd), and lowest on risk and compliance (30th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LNTH filings, in plain words
Have members of Congress traded LNTH?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Gilbert Cisneros dated 2025-01-28.
Read the full summary
Members of Congress have disclosed trades in LNTH, none in the last year; the latest on record is a purchase by Gilbert Cisneros dated 2025-01-28. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
